Page last updated: 2024-11-13
picrinine
Description
picrinine: structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
picrinine : A natural product with formula C20H22N2O3 that is the member of the akuammiline family of alkaloids, first isolated in 1965 from the leaves of Alstonia scholaris. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]
| Flora | Rank | Flora Definition | Family | Family Definition |
|---|
| Alstonia | genus | A plant genus of the family APOCYNACEAE. Members contain echitovenidine, echitamine, venenatine (an indole alkaloid), and anti-inflammatory triterpenoids[MeSH] | Apocynaceae | The dogbane family of the order Gentianales. Members of the family have milky, often poisonous juice, smooth-margined leaves, and flowers in clusters.[MeSH] |
Cross-References
Synonyms (5)
| Synonym |
|---|
| 4684-32-6 |
| picrinine |
| chebi:70505 , |
| CHEMBL590510 |
| MS-25152 |
Research Excerpts
Overview
Picrinine was first isolated in 1965 from the leaves of Alstonia scholaris. Picrinine is a member of the akuammiline family of alkaloids.
Toxicity
| Excerpt | Reference | Relevance |
|---|
| " Safety was assessed biochemically and clinically throughout the study, and drug re-excitation research was conducted to verify the correlation between investigational product and minor adverse events." | ( Pharmacokinetics and safety evaluation in healthy Chinese volunteers of alkaloids from leaf of Alstonia scholaris: A multiple doses phase I clinical trial.
Cao, WY; Gao, HY; Gao, R; Gou, ZP; Li, QN; Li, R; Lu, F; Luo, XD; Sun, MY; Wang, SG; Xiong, ZL; Zhang, WT; Zhao, Y; Zhao, YL; Zhao, YP; Zi, MJ, 2019) | 0.51 |
| " For the safety evaluation of CALAS, two cases of minor adverse events were observed during the trial, but the drug re-excitation research indicated that these two adverse events were related to the individual's physiological variation." | ( Pharmacokinetics and safety evaluation in healthy Chinese volunteers of alkaloids from leaf of Alstonia scholaris: A multiple doses phase I clinical trial.
Cao, WY; Gao, HY; Gao, R; Gou, ZP; Li, QN; Li, R; Lu, F; Luo, XD; Sun, MY; Wang, SG; Xiong, ZL; Zhang, WT; Zhao, Y; Zhao, YL; Zhao, YP; Zi, MJ, 2019) | 0.51 |
| " The CALAS was safe in healthy subjects under the current dose regimen." | ( Pharmacokinetics and safety evaluation in healthy Chinese volunteers of alkaloids from leaf of Alstonia scholaris: A multiple doses phase I clinical trial.
Cao, WY; Gao, HY; Gao, R; Gou, ZP; Li, QN; Li, R; Lu, F; Luo, XD; Sun, MY; Wang, SG; Xiong, ZL; Zhang, WT; Zhao, Y; Zhao, YL; Zhao, YP; Zi, MJ, 2019) | 0.51 |
Pharmacokinetics
| Excerpt | Reference | Relevance |
|---|
| " The method was successfully applied to a pharmacokinetic study involving a single oral administration of 108 mg/kg Dengtaiye tablet to rats." | ( Simultaneous quantitation of the diastereoisomers of scholarisine and 19-epischolarisine, vallesamine, and picrinine in rat plasma by supercritical fluid chromatography with tandem mass spectrometry and its application to a pharmacokinetic study.
Cao, J; Gu, J; Liang, C; Sun, L; Xu, Y; Yang, Y; Yang, Z, 2016) | 0.65 |
| " 19-epischolaricine, vallesamine and picrinine were match to the linear pharmacokinetic characteristics, but scholaricine conformed to the characteristics of nonlinear pharmacokinetics." | ( Pharmacokinetics and safety evaluation in healthy Chinese volunteers of alkaloids from leaf of Alstonia scholaris: A multiple doses phase I clinical trial.
Cao, WY; Gao, HY; Gao, R; Gou, ZP; Li, QN; Li, R; Lu, F; Luo, XD; Sun, MY; Wang, SG; Xiong, ZL; Zhang, WT; Zhao, Y; Zhao, YL; Zhao, YP; Zi, MJ, 2019) | 0.79 |
Roles (5)
| Role | Description |
|---|
| plant metabolite | Any eukaryotic metabolite produced during a metabolic reaction in plants, the kingdom that include flowering plants, conifers and other gymnosperms. |
| antitussive | An agent that suppresses cough. Antitussives have a central or a peripheral action on the cough reflex, or a combination of both. Compare with expectorants, which are considered to increase the volume of secretions in the respiratory tract, so facilitating their removal by ciliary action and coughing, and mucolytics, which decrease the viscosity of mucus, facilitating its removal by ciliary action and expectoration. |
| anti-asthmatic agent | Any compound that has anti-asthmatic effects. |
| analgesic | An agent capable of relieving pain without the loss of consciousness or without producing anaesthesia. In addition, analgesic is a role played by a compound which is exhibited by a capability to cause a reduction of pain symptoms. |
| anti-inflammatory agent | Any compound that has anti-inflammatory effects. |
| [role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Drug Classes (5)
| Class | Description |
|---|
| organic heteropentacyclic compound | |
| methyl ester | Any carboxylic ester resulting from the formal condensation of a carboxy group with methanol. |
| polycyclic ether | |
| indole alkaloid | An alkaloid containing an indole skeleton. |
| alkaloid ester | |
| [compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res] |
Research
Studies (11)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (18.18) | 29.6817 |
| 2010's | 8 (72.73) | 24.3611 |
| 2020's | 1 (9.09) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |
Market Indicators
Research Demand Index: 22.86
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.
| Metric | This Compound (vs All) |
|---|
| Research Demand Index | 22.86 (24.57) | | Research Supply Index | 2.56 (2.92) | | Research Growth Index | 4.84 (4.65) | | Search Engine Demand Index | 21.17 (26.88) | | Search Engine Supply Index | 2.00 (0.95) |
| |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|
| Trials | 1 (9.09%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (90.91%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] |